Benveniste O, Hilton-Jones D. The role of rituximab in the treatment of myasthenia gravis. European Neurological Review 2010;5(2):95–100. http://doi.org/10.17925/ENR.2010.05.02.95
Cea G, Benatar M, Verdugo RJ, Salinas RA. Thymectomy for non-thymomatous myasthenia gravis. Cochrane Database Syst Rev 2013;(10):CD008111. https://www.ncbi.nlm.nih.gov/pubmed/24122674
De Feo LG, Schottlender J, Martelli NA, Molfino NA. Use of intravenous pulsed cyclophosphamide in severe, generalized myasthenia gravis. Muscle Nerve 2002;26(1):31–6. https://www.ncbi.nlm.nih.gov/pubmed/12115946
Mehndiratta MM, Pandey S, Kuntzer T. Acetylcholinesterase inhibitor treatment for myasthenia gravis. Cochrane Database Syst Rev 2014;(10):CD006986. https://www.ncbi.nlm.nih.gov/pubmed/25310725
Nowak RJ, Dicapua DB, Zebardast N, Goldstein JM. Response of patients with refractory myasthenia gravis to rituximab: a retrospective study. Ther Adv Neurol Disord 2011;4(5):259–66. https://www.ncbi.nlm.nih.gov/pubmed/22010039
Sussman J, Farrugia ME, Maddison P, Hill M, Leite MI, Hilton-Jones D. Myasthenia gravis: Association of British Neurologists' management guidelines. Pract Neurol 2015;15(3):199–206. https://www.ncbi.nlm.nih.gov/pubmed/25977271
UK Medicines Information (UKMi). How do you convert an oral pyridostigmine or neostigmine dose to a parenteral neostigmine dose? [Q&A 248.4]. [London: NHS Specialist Pharmacy Service; 2015.
Wolfe GI, Kaminski HJ, Aban IB, Minisman G, Kuo HC, Marx A, et al. Randomized trial of thymectomy in myasthenia gravis. N Engl J Med 2016;375(6):511–22. https://www.ncbi.nlm.nih.gov/pubmed/27509100
